Evidence map›Paper›PMID 40357209›Full record

ArticleFrontiers in endocrinology2025

The TUITEK

Ekaterina Koledova, Pen-Hua Su, Yen-Ju Chen, Aria Assefi, Matias Debicki, Debbie Cooke, Amrit Jheeta, Alexander B Jones, Jung Eun Moon

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ekaterina KoledovaGlobal Medical Affairs Cardiometabolic & Endocrinology, Merck Healthcare KGaA, Darmstadt, Germany.
Pen-Hua SuSchool of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Yen-Ju ChenMedical and Clinical Affairs Department, Merck Ltd., Taipei, Taiwan.
Aria AssefiMedical Department, Merck S.A., Buenos Aires, Argentina.
Matias DebickiPatient Support Program, Merck S.A., Buenos Aires, Argentina.
Debbie CookeAtlantis Health Ltd, London, United Kingdom.
Amrit JheetaAtlantis Health Ltd, London, United Kingdom.
Alexander B JonesinScience Communications, London, United Kingdom.
Jung Eun MoonDepartment of Pediatrics, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Recombinant human growth hormone (r-hGH) can improve or normalize growth outcomes in pediatric patients with growth hormone deficiency, but poor adherence to the treatment regimen limits treatment effectiveness. TUITEK Patients and methods: A prospective pre-post research was conducted across the combined population of caregivers of patients with short stature receiving r-hGH treatment in the TUITEK Results: In total, data from 409 caregivers were available. Involvement in the TUITEK Conclusions: The TUITEK

Indexed as

CaregiversGrowth DisordersHuman Growth HormoneMedication AdherenceAdolescentAdultArgentinaChildFemaleHealth Knowledge, Attitudes, PracticeHumansMaleMiddle AgedProspective StudiesRepublic of KoreaTaiwanHuman Growth Hormoneadherence behaviorsbehavior change techniquesgrowth hormone deficiencypatient support programrecombinant human growth hormone

Identifiers

PMID40357209
PMCPMC12066293

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.